No Data
No Data
No Data
No Data
No Data
Alvotech Provides Regulatory Update on Second Biologics License Application for AVT02
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Alvotech's second Biologics License Application (BLA) for AVT02, a high-concentration biosimilar candidate for Humira (adalimumab).
GlobeNewswireJun 28, 2023 19:00 ET
Alvotech (NASDAQ:ALVOW) Short Interest Up 178.3% in March
Alvotech (NASDAQ:ALVOW – Get Rating) was the recipient of a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 16,700 shares, a growth of 1
Defense WorldMar 28, 2023 03:23 ET
Short Interest in Alvotech (NASDAQ:ALVOW) Grows By 39.5%
Alvotech (NASDAQ:ALVOW – Get Rating) was the target of a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 6,000 shares, a growth of 39.
Defense WorldMar 13, 2023 05:13 ET
Serengeti Asset Management LP Raises Stock Holdings in Alvotech (NASDAQ:ALVOW)
Serengeti Asset Management LP raised its position in Alvotech (NASDAQ:ALVOW – Get Rating) by 23.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securiti
Financial News LiveJan 4, 2023 11:42 ET
No Data
No Data